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Background: Globally, trans people are disproportionately affected by HIV, but research on strategies to
increase testing are limited. SELPHI is a randomised-controlled-trial (RCT) of 10,135 cis men, trans men, and
trans women reporting lifetime anal intercourse with male partners (cis or trans), evaluating whether the
offer of free HIV self-testing (HIVST) increases diagnosis. This subgroup analysis from the SELPHI RCT aims to
describe key HIVST outcomes and HIVST acceptability for trans people.
Methods: SELPHI recruited using social networking and trans focused social media. Participants were randomised
60/40 to baseline HIVST (BiosureTM) (BT) vs no baseline HIVST (nBT); and at 3-months (if completed the survey
and reported recent CAI) 50/50 to 3-monthly HIVST (RT) vs no repeat HIVST (nRT). Outcomes were self-reported
through online surveys. We conducted a qualitative study of semi-structured peer-led participant interviews
(n = 20) exploring HIVSTmotivations and experiences. These were analysed using a framework approach.
Findings: SELPHI recruited and randomised 118 trans men and trans women (94 trans men, 24 trans women),
of whom 20 (16 trans men, 4 trans women) underwent the second randomisation. Median age at baseline
was 29 (IQR: 22, 37), 79% were white, 79% were UK born, 37% had degree level education, and 31% had never
tested for HIV. 62% (n = 59) of trans men completed the 3-month survey, but survey completion by trans
women in nBT was too low (1/11) for randomised comparison. In trans men HIV testing uptake by 3 months
was significantly higher in BT (95% 36/38) vs nBT (29%, 6/21) (RR=3.32 (1.68, 6.55) p<0.001). Trans people
randomised to RT reported 3 times higher rate of HIV testing compared to nRT during the two-year follow-
up (IRR 3.66 (1.86, 8.01) p<0.0001). STI testing frequency (mean number of tests during each 13 week period/
2-year follow-up) was not significantly different across interventions: RT (0.03) and nRT (0.01) (IRR=1.86
95%CI; 0.77, 5.15; p = 0.15). Social harms were rare. Acceptability was very high in BT: 97% (38/39) found
instructions easy to understand, 97% (37/38) found the HIVST simple to use and 100% (39/39) reported good
overall experience. In interviews, reported HIVST benefits included increased autonomy, privacy, conve-
nience and avoidance of health care providers perceived to be discriminatory and services that increased
dysphoria. Minor lancet and test processing issues were reported.
Interpretation: HIVST significantly increased testing uptake and frequency in trans men and trans people
overall, although recruitment and retention of trans women was low. HIVST acceptability was high and indi-
cates easy access to this novel technology may increase HIV testing access for this key population.
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Research in context
Evidence before this study
Trans people are a key population in the HIV response with pro-
nounced HIV testing need. However few data exist on optimal
approaches and interventions to support these groups.
The HIVST evidence base has evolved rapidly since 2012. A
systematic mapping and reviewing exercise conducted to
update the WHO HIV self-testing guidelines informs this study.
Observational evidence from the US and Latin America suggests
that HIVST is acceptable to trans women and may increase test-
ing uptake by providing a private, convenient testing method
which reduced the need to access clinics. The potential impact
on incidence of harm is uncertain and is an important issue
given the high levels of background violence faced by trans
people.
The meta-analysis which underpins this research (see
Witzel et al 2020) identified 10 randomised controlled trials
(RCTs) evaluating HIVST amongst key populations, 2 of which
included trans people. These two previous RCTs have not
reported their trans participants (n = 72) separately from cis-
gender MSM, meaning that outcomes for this group are
unknown.
Added value of this study
This study provides the first randomised comparison of HIVST
outcomes for this population and includes the largest sample of
trans people reported in HIVST RCT literature to date. This evi-
dence demonstrates that HIVST is highly acceptable and can
dramatically increase HIV testing uptake and frequency with-
out negatively impacting on STI testing. Self-testing acceptabil-
ity in this group was very high in both quantitative and
qualitative enquiry.
This research also demonstrates the critical issues with ser-
vice access faced by trans people in the UK which increases the
acceptability and utility of remote HIV testing options.
Implications of all the available evidence
On the basis of this study and the other existing evidence
reporting high acceptability, HIVST can be commissioned for
trans men and trans women. Pilot and demonstration projects
providing HIVST to these groups should monitor proactively for
adverse events. In addition, the potential for HIVST to increase
HIV diagnoses in this group is uncertain, as is the potential
impact on linkage to care.
Sexual health services require investment in staff training as
well as clinical processes and procedures to ensure they are
able to provide appropriate care for trans people.
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Increasing uptake and frequency of HIV testing is a public health pri-
ority and is necessary to reduce HIV incidence globally. This is enshrined
in the UNAIDS 959595 targets whereby 95% of people living with
HIV know their status, 95% of those are on ART and 95% on ART have
virological suppression by 2030 [1]. Trans people and in particular trans
women are a key population at increased risk of HIV acquisition, yet are
severely underserved in the global response, including in HIV prevention
and testing research [2,3]. There is also a lack of data on the sexual health
needs of transmen andwomen in the UK, despite the fact that this group
is more likely to be diagnosed with HIV late, less likely to attend sexual
health clinics and less likely to test for HIV than cisgender men who
have sex withmen (MSM) [46].Trans people globally face barriers to HIV testing and prevention
services not experienced by other groups [7]. These barriers include
services which are not culturally appropriate, health care provider
hostility and lack of understanding, the risk of arrest and imprison-
ment and barriers surrounding trans visibility and associated vulner-
ability [5,710]. Trans women are also disproportionately
represented in sex work, leading to additional sexual health needs
which may be poorly met by existing services [11]. HIV testing rates
among trans people in the UK are sub-optimal, with 49% of 500 trans
participants reporting no lifetime HIV testing in a recent study [5].
HIV self-testing (HIVST) is a relatively novel testing modality
whereby people test themselves using a rapid diagnostic test, which
involves taking their own sample, processing the test and reading
their own result [12]. HIVST has been reported to reduce barriers
relating to stigma, privacy and inconvenient healthcare services and
can be delivered through a variety of mechanisms adapted to the
needs of specific populations. This testing approach was first recom-
mended by the World Health Organization in December 2016, with
updated guidelines released in December 2019 [13,14]. However
concerns remain regarding the potential of HIVST to lead to decreases
in STI testing and increases in risk behaviour and also the potential
for harms, such as coercion to test, negative impact on wellbeing or
relationships, as well as intimate partner violence [12,15].
RCT evidence regarding HIVST for trans people is scarce. Small
numbers of trans people (mostly trans women) (n = 72) have been
included in two RCTs recruiting cisgender MSM; but their data were
not reported separately [16,17,18]. Pilot and demonstration projects
including trans women in the US show that HIVST is an acceptable
and feasible method for delivering HIV testing both through clinic
distribution and for onward distribution to their sexual partners
[19,20]. No European evidence regarding trans people and HIVST
exists, and there is a general lack of qualitative data for these groups.
It is critical to generate evidence for trans people specifically
regarding the potential for HIVST to increase HIV testing uptake and
frequency and to understand key dimensions of acceptability for
trans people who access HIVST interventions. This subgroup analysis
aims to describe key HIVST outcomes (HIV testing uptake/frequency,
STI testing uptake/frequency, sero-status) and HIVST acceptability for
trans people.2. Methods
SELPHI (An HIV Self-Testing Public Health Intervention) is an RCT
which recruited 10,135 MSM (cis and trans) and trans women who
have anal sex with men. The study initially planned to include only
MSM (cis and trans), but the SELPHI community advisory group rec-
ommended expanding the inclusion criteria to trans women pro-
vided a separate analysis of trans participants was conducted. The
analysis we present here includes data on trans participants only.
In addition to the RCT data we also include a peer-led qualita-
tive sub-study to elicit more depth and nuance surrounding the
experiences of trans people concerning intervention usability and
acceptability.
2.1. RCT methods
SELPHI is an online RCT with two randomisations and two inter-
ventions, the protocol has been published elsewhere [21] and is
available in additional file 1. Participants were recruited through
social media, and online geo-location social and sexual networking
apps used predominantly by MSM but also trans women (Facebook,
Grindr, Scruff and Growlr). SELPHI began recruitment in February
2017 through a predefined pilot phase, recruiting 10% of its overall
sample [22]. Full recruitment began July 2017 and was completed in
February 2018. Eligible participants were MSM (cis and trans) and
Fig. 1. RCT schema with eligibility criteria for both randomisations.
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lifetime anal sex with men (cis or trans).
In the first randomisation, eligible participants were randomised
60/40 to an offer of a baseline HIVST (BT) vs standard of care (no
baseline testing (nBT)). In the second randomisation eligible partici-
pants were randomised 50/50 to offer of repeat HIVST (RT) vs stan-
dard of care (no repeat testing (nRT)). As the second randomisation
sought to detect incident infections during the trial only those whoreported a negative HIVST result in BT were included. Fig. 1 presents
a trial schema with eligibility for both randomisations.
The primary outcome of the trial was a confirmed HIV diagno-
sis; secondary outcomes included uptake and frequency of HIV
testing, frequency of STI testing and harms experienced during
SELPHI. Follow-up period for outcomes from randomisation A
(HIV and STI testing uptake) was 3-months; for randomisation B
outcomes (HIV and STI testing frequency) follow-up lasted 2
4 T.C. Witzel et al. / EClinicalMedicine 32 (2021) 100700years. Harms follow-up was at 18-months and 2 years for ran-
domisations A and B respectively.2.1.1. RCT data collection procedures
RCT infrastructure was online. When registering for SELPHI, par-
ticipants completed a survey confirming eligibility, giving consent to
participate and for linkage to national HIV surveillance databases,
and providing baseline demographic and behavioural details.
We used a two-stage gender question to identify trans partici-
pants. The first stage asked for gender identity (male, female, trans
male, trans female, non-binary) while the second question asked
assigned sex at birth (male, female, undetermined).
Following enrolment, additional surveys were delivered at two-
weeks (BT participants only) and three-months (all participants).
Those randomised to RT and nRT received three monthly surveys
from the date of their second randomisation. BT and nBT participants
received an end of study survey 18 months after enrolment; this
was delivered to RT and nRT participants 24 months after enrolment.
Three reminders were sent per survey.
Secondary outcomes were self-reported through these surveys.
HIVST uptake and frequency for the intervention arms (BT and RT)
were validated with delivery records kept by the trial team. Harms
data were self-reported.
Data for the primary outcome were provided by data linkage with
Public Health England’s HIV surveillance databases.2.1.2. Interventions
All kits distributed through SELPHI were BioSureTM 2nd generation
blood based HIVSTs. Full descriptions of the interventions and theo-
retical underpinnings can be found in prior publications [19,23,24].
Here we present an abridged version.
2.1.2.1. BT. Participants enrolled via an advert served on social media
and apps. During registration a sexual behaviour risk assessment was
delivered asking numbers of male partners and number of condom-
less anal intercourse (CAI) partners. Following randomisation to the
BT arm, an HIVST kit was delivered via post directly from the manu-
facturer. This was accompanied by a sleeve detailing additional sup-
portive information and signposting a helpline run by a community-
based organisation (Terrence Higgins Trust). Two-weeks following
kit delivery a short survey was delivered via email seeking to confirm
kit receipt, use and outcome, this survey was considered part of the
intervention. At three-months participants received a follow-up sur-
vey (considered part of trial infrastructure); those who were eligible
were randomised a second time to RT or nRT.
2.1.2.2. nBT. Participants randomised to nBT had a similar interven-
tion pathway to those in BT. However, in terms of intervention, rather
than receive a kit they were directed to an online widget into which
they could enter their postcode and identify their nearest HIV testing
opportunity. They did not receive the two-week follow-up compo-
nent of the intervention but received a three-month survey with the
same questions as in the BT questionnaire, except those about the
HIVST kit.
2.1.2.3. RT. Those who in BT were eligible were entered into a second
randomisation. If randomised to RT they were sent a new kit, identi-
cal to that in BT and with the same supportive information. At two-
weeks following kit delivery they received a result recording survey,
considered part of the intervention. At three-months participants
were emailed a testing reminder with a linked survey which
prompted the choice to receive a further HIVST, beginning the cycle
again. The risk assessment embedded within this survey was consid-
ered part of the intervention.2.1.2.4. RT. Those randomised to nRT were shown the widget identi-
fying testing locations. They received three-monthly surveys which
included the risk assessment.
2.1.3. Sample size determination
For the overall trial (including cis-MSM), sample size determina-
tion was based on the primary outcomes of confirmed HIV diagnosis
for those with prevalent and incident infections [19]. Formal sample
size determination was not determined for the trans sub-group prior
to RCT implementation, largely because this element was exploratory
and it was unclear how many trans participants we could recruit. Our
sample size is comparable to early HIVST RCTs including only MSM
[16,25].
2.1.4. Randomisation and allocation concealment
Both randomisations used random sequence generation by the
survey provider, randomising individual participants.
Due to the nature of the intervention participants could not be
blinded to their intervention condition. Chief investigators and the
trial statistician were unblinded to participant allocation and trial
outcomes to maintain participant safety and trial data validity. How-
ever all other SELPHI investigators were blinded.
2.1.5. Statistical methods
Our analysis plan for this sub-group mirrored that of the larger
RCT within which it was contained. All analyses were complete case
intention-to-treat.
Baseline demographic and behavioural variables were tabulated
and assessed for balance using a rank-sum test or chi-squared test as
appropriate.
Randomised comparisons and non-randomised acceptability
analyses were summarised and tabulated. Data are reported by trans
men, trans women and all trans participants (trans men and women
combined). Randomised comparisons for the first randomisation
were conducted using risk ratios. For the second randomisation, as
all participants did not necessarily complete all surveys, follow-up
time was estimated as 13 weeks for every survey completed (reflect-
ing the time between each scheduled follow-up survey). The rate of
testing using this follow-up time was then estimated and compared
by calculating the incidence rate ratio using Poisson regression. For
the primary outcome of HIV diagnosis, the data was linked with
national HIV surveillance databases at Public Health England. Analy-
ses were performed using Stata v16.0
2.2. Qualitative sub-study
We conducted a qualitative sub-study to explore dimensions of
acceptability and generate a nuanced understanding of the potential
of HIVST in addressing unmet testing need for trans people. We
worked with a trans woman peer researcher who contributed to
study design, data collection and analysis to engage trans participants
and to develop additional insights. Interviews were conducted
between April and October 2019. Methods for the qualitative sub-
study are described below.
2.2.1. Recruitment and sampling
All 87 trans participants who provided consent to be contacted for
qualitative interviews at enrolment for the RCT were considered eli-
gible for this sub-study. Upon reaching 20 interviews we reviewed
the data paying close attention to completeness of themes and nega-
tive cases. Through this process we assessed we had achieved the-
matic saturation and thus ended recruitment. We aimed to achieve
diversity in the sub-study sample with regards to gender identity
(oversampling trans women for this component because of their
small numbers in the trial), RCT intervention allocation and age. One
participant was not randomised when they joined SELPHI and
Table 1
Randomised trial baseline demographic details.
Demographic detail Trans men Trans women All
N = 94 N = 24 N = 118
Included in Randomisation B 16 (17%) 4 (17%) 20 (17%)
Median (IQR) age (years) 28 (21, 36) 33 (26, 38) 29 (22, 37)
Age category
1625 years 37 (40%) 6 (25%) 43 (36%)
2640 years 39 (41%) 14 (58%) 53 (45%)
41+ years 18 (19%) 4 (17%) 22 (19%)
Born in the UK 76 (81%) 17 (71%) 93 (79%)
Ethnicity
White 77 (82%) 16 (67%) 93 (79%)
Asian 4 (4%) 5 (21%) 9 (8%)
Black 2 (2%) 0 2 (2%)
Mixed 6 (6%) 1 (4%) 7 (6%)
Other/Don’t know/Not disclosed 5 (5%) 2 (8%) 7 (6%)
Highest educational qualification
Low1 22 (23%) 12 (50%) 34 (29%)
Medium2 31 (33%) 8 (33%) 39 (33%)
High3 40 (43%) 4 (17%) 44 (37%)
Sexual orientation
Gay 34 (36%) 3 (13%) 37 (31%)
Bisexual 31 (32%) 9 (38%) 40 (34%)
Straight 1 (1%) 4 (17%) 5 (4%)
Other 6 (6%) 2 (8%) 8 (7%)
No term/Not disclosed 22 (23%) 6 (25%) 28 (24%)
Partner numbers (3 months)
0 23 (24%) 3 (13%) 26 (22%)
1 32 (34%) 9 (38%) 41 (35%)
24 23 (24%) 8 (33%) 31 (26%)
5+ 16 (17%) 4 (17%) 20 (17%)
Previous HIV test
Never 27 (29%) 9 (38%) 36 (31%)
<12 months 47 (50%) 9 (38%) 56 (47%)
>12 month 20 (21%) 5 (21%) 25 (21%)
1 GCSEs and below.
2 A-levels and further education below degree level.
3 Degree+.
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included in the qualitative sub-study.
Participants were contacted by the peer researcher via email with
the participant information sheet and were offered the choice
between being interviewed by a trans woman (second author) or a
cisgender gay man (first author).
2.2.2. Interviews and data analysis
The topic guide (available in additional file 2) was developed by first
and second authors, adapting a previous topic guide used in a separate
sub-study including cis-MSM [23,24]. This process focused on adapting
questions and including new ones relevant to trans people.
The topic guide covered experiences of health care; mental health
and gender identity services; previous HIV testing experiences; moti-
vations for seeking HIVST; experiences of SELPHI trial infrastructure
and potential intervention adaptations. Our analysis draws from the
latter four of these.
Participants were interviewed over the phone and through video
calling, with a minority (n = 2) interviewed in person. Interviews lasted
between 45 and 90min, were recorded and transcribed verbatim.
Analysis combined framework and thematic approaches [26,27].
Our framework drew from emerging themes identified during data
generation, the wider literature around trans peoples’ experiences of
HIVST / sexual health services, theorised key components of interven-
tion acceptability from formative and RCT acceptability work and sys-
tematic reviews [18,23,28-30]. The analysis framework can be found
in additional file 3.
2.2.3. Registration, approval and ethics
SELPHI was prospectively registered with the ISRCTN (ref:
ISRCTN20312003). Ethical approval was sought from and granted by
the University College London (UCL) (ref: 11,945) and the London
School of Hygiene and Tropical Medicine (LSHTM) (ref: 9233/001).
2.2.4. Role of funding
The funder had no role in study design; in the collection, analysis,
and interpretation of data; in the writing of the report; or in the deci-
sion to submit the paper for publication.
3. Results
SELPHI recruited 118 trans participants. The majority (n = 94, 80%)
were trans men, median age of 29, 79% (n = 93) white, 79% (n = 93)
born in the UK, 37% (n = 44) highly educated and 31% (n = 36) had
never previously tested for HIV. All 118 participants were included in
the first randomisation, while 20 were also randomised in the sec-
ond. There were no substantial imbalances across arms of baseline
demographics. Table 1 presents baseline data. Fig. 2 presents a trial
flow diagram with survey completion rates.
3.1. RCT outcomes
Below we present outcomes from both randomisations, as well as
acceptability variables from the first SELPHI HIVST for trans men and
trans people overall. Survey completion rates for trans women in nBT
(1/11) and the total number of trans women randomised in RT or nRT
(n = 4) were too low for randomised comparisons with this group.
Table 2 presents comparisons for HIV and STI testing uptake and fre-
quency and includes descriptive results for trans women.
3.1.1. HIV outcomes
No trans participants received a confirmed HIV diagnosis during
the 2-year trial follow-up. HIV testing uptake at 3 months was signifi-
cantly higher in BT (95%, 36/38) vs nBT (29%, 6/21) amongst trans
men (RR=3.32; 1.68, 6.55, p<0.001) and in all trans participants
(RR=3.43, 95%CI 1.72, 6.81, p<0.001). During the two-year follow-upperiod trans men randomised to RT reported 3 times the rate of HIV
testing compared to nRT (IRR 2.98 95%CI 1.50, 6.56; p = 0.0002), as
did trans people overall (IRR 3.66 95%CI 1.86, 8.01; p<0.0001).3.1.2. STI outcomes
STI testing in the 3 months after enrolment was similar for trans
men across BT (29%, 11/38) vs nBT (29% 6/21) (RR=1.01 95%CI; 0.44,
2.35; p = 0.98) and for trans people overall: BT (26%, 12/46) vs nBT
(27% (6/22)) (RR=0.96; 95% CI 0.41, 2.12; p = 0.92). Over the two-year
follow-up frequency (mean number of STIs tests per 13 week period)
did not differ significantly for trans men RT (0.02) and nRT (0.02) (IRR
1.20 95%CI 0.46, 3.49; p = 0.69) and was not significantly different for
trans people overall RT (0.03) and nRT (0.01) (IRR=1.86 95%CI; 0.77,
5.15; p = 0.15).3.1.3. Harm
No participants in either arm reported negative impacts on well-
being or relationships in exit surveys. No false positive test results
were reported. No participants reported they were pressured or per-
suaded to test when they did not want to. However 2 participants in
the repeat testing arm (one trans man and one trans woman)
reported pressuring or persuading someone else to test when they
did not want to.3.2. Acceptability
HIVST was highly acceptable for trans men and women in the
baseline testing arm: 97% (38/39) found instructions easy to under-
stand, 97% (37/38) found the test simple to use and 100% (39/39)
reported a good overall experience.
Fig. 2. SELPHI trans sub-analysis flow diagram.
Table 2
Intervention outcomes.
Randomisation A outcomes BT% (n) nBT% (n) RR (95% CI) P value
HIV testing uptake (3 months)
All 93% (43/46) 27% (6/22) 3.43 (1.72, 6.81) <0.0001
Trans men 95% (36/38) 29% (6/21) 3.32 (1.68, 6.55) <0.0001
Trans women 88% (7/8) 0 (0/1) N/A N/A
STI testing uptake (3 months)
All 26% (12/46) 27% (6/22) 0.96 (0.41, 2.21) 0.92
Trans men 29% (11/38) 29% (6/21) 1.01 (0.44, 2.35) 0.98
Trans women 13% (1/8) 0 (0/1) N/A N/A




IRR (95% CI) P value
HIV testing frequency (2 years) All N = 7
Trans men N = 6
All N = 12
Trans men N = 10
All 0.07 0.02 3.66 (1.86, 8.01) <0.0001
Trans men 0.07 0.02 2.98 (1.50, 6.56) 0.0002
STI testing frequency (2 years)
All 0.03 0.01 1.86 (0.77, 5.15) 0.15
Trans men 0.02 0.02 1.20 (0.46, 3.49) 0.69
Note: estimates could not be generated for trans women due to the very small sample size. In Randomisation B, one trans
women reported always taking a HIV test (RT), and two reported never taking a HIV test in follow-up (one nRT, one RT). CI: con-
fidence interval; IRR: incidence rate ratio; RR: risk ratio.
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We interviewed a diverse sample of participants (n = 20) from all
trial arms. Below we present results of our qualitative analysis, focus-
ing on barriers and facilitators to HIV testing services which shaped
HIVST engagement; intervention experiences and RCT infrastructure
acceptability. Table 3 provides demographic data from qualitative
sub-study sample.
3.3.1. Motivations and barriers to HIV testing services
A number of barriers to accessing sexual health and community
HIV testing services were described. These barriers were the primary
motivation for HIVST uptake through the trial, profoundly shaping
acceptability as HIVST allowed for the bypassing of clinical services
for HIV testing. Many barriers and facilitators described are common
across key population groups when considering standard HIV testing
services (e.g. inconvenient clinic opening hours, HIV stigma, physical
distance, fear of a positive result) [31]. Here we describe barriers and
facilitators specific to trans men and trans women. These clustered
around three primary areas: (i) skills, empathy and cultural compe-
tence; (ii) systems, processes and clinic design and (iii) gender iden-
tity, dysphoria and reticence.
3.3.1.1. Skills, empathy and cultural competence. significant problems
with clinic personnel were reported by those who had previously
accessed clinic-based HIV testing, contributing to substantial HIVST
acceptability. Experiences of overt discrimination from health care
professionals were rare, more commonly personnel lacked the neces-
sary skills, empathy and cultural competence to meet the needs of
trans people.
A trans man reported being misgendered and having his sexual
orientation doubted while being denied post-exposure prophylaxis
(PEP) at a London sexual health clinic following condomless inter-
course with a cis-MSM:Table 3
Qualitative sub-study demographic details
Demographic characteristics Participant numbers
N=20
Age 16 - 25 years 7 (35%)
26 - 40 years 6 (30%)
41+ 7 (35%)
Gender Trans women 7 (35%)
Trans man 12 (60%)
Non-binary 1 (5%)
Ethnicity White 16 (80%)
Black 2 (10%)
Latin American 1 (5%)
Asian -
Other / mixed -
Undisclosed 1 (5%)
Sexual orientation Heterosexual 2 (10%)
Gay 7 (35%)
Bisexual 6 (30%)
Don’t use a term 1 (5%)
Undisclosed 4 (20%)




Randomisation RT 4 (25%)
BT 10 (50%)
nBT 5 (25%)
Not randomised 1 (5%)
1 GCSEs and below
2 A-levels and further education below degree level
3 Degree+I’m not the most masculine-looking person in the world, I have to
admit. But I did have a little bit of facial hair. And not to be glib
but I have got body hair. And one said, “I wouldn’t worry about it
‘cause he’s probably heterosexual.” And that was just quite frus-
trating. ‘Cause I’d started the transition [. . .] I’d been on testoster-
one for several years. [. . .] It’s like I wasn’t trans, [the way] he was
talking about it. And so [he felt] I wasn’t particularly at risk of any-
thing. (28-year old trans man, baseline testing arm)
These types of experiences were very common, with staff
often misgendering trans people, treating them as a burden, eras-
ing their sexual orientation and/or gender identity and disregard-
ing their perceptions of risk. Conversely, positive experiences
usually focused on affirming interactions with clinical staff,
largely (but not wholly) in services specifically designed for trans
people. The potential for avoidance of any clinical staff or facili-
ties felt to be hostile or not trans competent, led to substantial
enthusiasm for HIVST.
3.3.1.2. Systems, processes and clinic design. With the exception of
services created and run for and by trans people, existing systems
within sexual health services were usually not designed with the
needs of trans people in mind. These services, which often advertised
as being LGBT inclusive, were felt only to cater to cis-MSM. This was
especially true when considering clinic pathways which emphasised
the male/female sex binary rather than gender identity. Experiences
of encountering clinics which did not have established processes for
trans patients was common.
They don’t have in their system that I am a trans woman. So they
always. think that I’m a [cis] woman. Because I don’t have vagina
yet, so they always give me the test for vagina. So I have to go
always to the reception desk to tell them, sorry, but I don’t have
vagina yet. (42-year-old trans woman, repeat testing)
These issues with clinic processes centred around record keeping
systems and pathways that relied on biological conceptualisations of
sex rather than social understandings of gender. There were also sig-
nificant issues with systems which did not represent the diversity in
anatomy represented in trans men and trans women, coming both
from hormone treatment and gender affirming procedures. Inflexibil-
ity in systems was common; staff were often required to take ad hoc
approaches to providing care to trans patients.
It was only now that I live as a man, and that I have a half and half
body if you like, so I’m a man with a vagina, so their system
[doesn’t account for that], in the end I think they had to draw
things on, use one [file] and draw it onto the other. We used the
female one and then drew things on that [. . .] of course, my vagina
doesn’t look like that, because it’s changed since I’ve been taking
testosterone. (52-year-old trans man, repeat testing)
SELPHI was felt to be more appropriately trans inclusive, with
HIVST providing a discreet testing method which was embedded
within systems which were designed for participants from a range of
genders.
3.3.1.3. Gender identity, dysphoria and reticence. Personal concerns
specific to gender identity were a major barrier to accessing clinics.
These ranged from worries that gender affirming treatments could
be withheld should an individual have a positive HIV diagnosis, to
concerns about experiencing gender dysphoria when describing
body parts.
Like I have very, very bad chest dysphoria, and bottom dysphoria
didn’t bother me so much. But the idea of going and getting tested
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of dysphoria. (20-year-old trans man, no baseline testing)
Gender dysphoria and concerns about discussing one's own body
were described as being pronounced in the early stages of transition,
a time when often individuals were also navigating changes in sexual
orientation, desire and practice. HIVST provided a sense of privacy
and autonomy, which ameliorated testing barriers.3.3.2. Intervention acceptability
This section describes intervention acceptability and kit use expe-
riences. It focuses on initial engagement with SELPHI, capability con-
cerns, support and behaviour changes.
3.3.2.1. Appeal, attraction and engagement. HIVST was felt to be a use-
ful, new technology which provided personal control over the HIV
testing process; a highly valued trait. The RCT adverts were described
as informative and helpful in highlighting benefits of self-testing.
Those who were recruited through adverts which focused solely on
HIVST facilitators and were therefore not specifically trans inclusive
assumed they would not be eligible and were surprised when they
attempted to sign up that trans men and women were included in
the RCT.
3.3.2.1. Capability, cognition and ease of use. The HIVST kits were
almost universally described as straightforward to operate and the
instructions as easy to understand. There were some minor issues
with the lancet and test processing stage (e.g. difficulty using the lan-
cet, errors in correctly inserting test stick into the pot containing
reagent), although none reported they could not complete a test.
Those receiving repeat testing described any capability issues as
resolving by the second test.
3.3.2.2. Care, support and follow-up. Emotional support following
testing was drawn primarily from social networks for those requiring
it, largely from friends, family and trans peers. A number of partici-
pants reported testing with others present, primarily to help with
test processing but also for emotional support. For those who were
socially isolated, support was mostly drawn from online sources with
message boards and closed Facebook groups identified as a key site
of engagement for health information.
3.3.2.2. Impacts, outcomes and expectations. Increased HIV testing fre-
quency for those receiving repeat HIVST was commonly reported.
This was perhaps due to low levels of prior testing, itself partly
because of a general lack of norms emphasising the need for frequent
testing. Two participants reported having less sex following HIVST,
but did not attribute it to the technology. Already low uptake of STI
testing for many participants meant that most did not feel accessing
HIVST would reduce their STI testing frequency.3.3.3. RCT infrastructure acceptability
Here we describe data related to the process evaluation questions
in the RCT, specifically investigating the functioning of trial infra-
structure and acceptability of the questions in surveys.
Few issues with RCT function were reported; on the whole experien-
ces matched expectations of being involved in research. Registration,
enrolment and follow-up surveys arrived as expected. Kits were deliv-
ered promptly and undamaged. For one participant the randomisation
process failed and they were left waiting for a kit which never arrived.
The number, timing and frequency of surveys was on the whole
described as appropriate and in line with expectations, although one
participant reported finding surveys annoying and cumbersome.
Questions asked in surveys were largely felt to be fair, balanced and
appropriate for the trans population.The two-stage gender question used was universally popular and
praised for providing a range of options and for the ability to accu-
rately capture data. One participant however expressed desire to
select more than one gender option to better reflect their identity
and lived experience.
While most found the sexual behaviour questions to be appropri-
ate and relevant, two trans male participants felt questions about
anal sex with men were not relevant to them as it did not reflect the
range of sexual practices trans men are likely to engage in or the
anatomy of trans men.
4. Discussion
SELPHI recruited a modest if diverse sample of 118 trans peo-
ple who have sex with men. The majority (80%) were trans men,
most were white and born in the UK. Just over a third were edu-
cated to degree level and 31% had never previously tested for
HIV. Uptake and testing frequency were significantly higher in
intervention arms than nBT and nRT arms, with no adverse
impacts on STI testing uptake or frequency. The test kit was per-
ceived to be highly acceptable, easy to use, and the vast majority
reported a good overall experience.
Previous studies have investigated the experiences of trans people
with HIVST in other (non-European) settings; this work adds weight
to the conclusion that HIVST is highly acceptable to this group in a
range of settings [18,20,32]. We also demonstrate significant unmet
testing need; 31% of trans men and women had not previously tested
for HIV, this is more than double the 15% of MSM (cis and trans com-
bined) from the wider trial who had not previously tested [33].
Qualitative data suggest the primary driver of HIVST uptake for
trans people was issues with inaccessible and inappropriate clinical
services which created pronounced barriers to accessing testing and
care. These barriers, which arose de novo in this research, clustered
around the themes of skills, empathy and cultural competence; sys-
tems, processes and clinic design as well as gender identity, dyspho-
ria and reticence. The primacy of these issues suggest generic HIV
testing services are neither accessible nor appropriately tailored for
trans people in England and Wales, including those services that
advertise as LGBT inclusive. These findings are consistent with
research from the UK and other settings [5,7-10]. It should be noted
that services designed specifically for trans people were very highly
valued.
These data also demonstrate the HIVST intervention was
attractive, easy to use and included sufficient follow-up relative
to need. Generally, participants recognised that SELPHI was
designed primarily for cis-MSM but felt the amount it was tai-
lored to trans men and trans women was adequate. Trial infra-
structure was largely felt to be appropriate. However a minority
(n = 2) reported concerns with the trial focus on anal intercourse
as they felt this did not necessarily reflect the diversity in sexual
practice for trans MSM specifically.
As trans people face barriers to HIV services and poor HIV health
outcomes [8,34], services delivering HIVST to trans people in the UK
should be implemented to support this group. Tailored and targeted
HIVST interventions are likely to be acceptable and feasible to deliver.
Evidence suggests HIVST does not lead to unintended negative out-
comes in this group, especially around decreases in STI testing rates
(although these were low in all arms). In addition, we found little evi-
dence of increased harms in the HIVST groups. Additional consider-
ation needs to be included in order to increase engagement with
trans people more widely. Indeed, including additional delivery
mechanisms may be helpful in increasing uptake across a wider
group of trans people, especially if delivered alongside services which
provide gender affirming care, and through mechanisms which
increase convenience (e.g. through click-and-collect systems). A fur-
ther avenue of exploration includes peer HIVST initiatives, potentially
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well as the provision of STI self-sampling alongside HIVST in a way
which recognises the diversity of need within the trans population.
This is the first study of HIVST among trans people in Europe, and
the first RCT to report HIVST data of trans people separately from cis-
MSM [16,17]. Never-the-less some limitations are noted.
Recruiting trans men and trans women was extremely challeng-
ing. This was partly due to the lower proportion of trans people using
geo-location sexual networking apps than cis-MSM, an issue we
sought to ameliorate through increased use of social media and trans
specific recruitment. Because there are no reliable estimates of the
demographic make-up of the trans community in the UK it is unclear
whether our sample is representative. However, given the very low
number of trans women who participated this sample is almost cer-
tainly more heavily weighted towards trans MSM.
We also only recruited participants who identified as trans men or
trans women, not those who identified as non-binary which is per-
haps the most significant limitation in this work and which remains a
critical research gap. In addition, people identifying as women rather
than trans women would not reach the next survey question before
they would have the opportunity to answer ‘sex at birth’, potentially
inadvertently excluding some trans women. Future work with trans
people should provide gender options which include both cis and
trans people in both male and female categories alongside suitable
non-binary categories. This approach, with a follow-on assigned sex
at birth question, is more affirming of trans identities.
Although 67% of trans men completed the 3-month survey, and
retention of this group was adequate in randomisation B, retention of
trans women was an issue especially in the nBT and nRT arms. This
means that randomised analyses could not be completed for this
group. These analyses therefore reflect only the experiences of trans
men and trans people overall.
In addition, although uptake of HIVST was validated in BT and RT
arms, HIV testing in nBT and nRT were self-reported, as were STI test-
ing outcomes across all arms. This may have introduced recall bias or
social desirability bias, perhaps overestimating rates of HIV and STI
testing.
Using condomless anal intercourse as an inclusion criteria for the
overall trial and for the second randomisation may have restricted
access to the trial for trans people who do not have anal sex and
instead have other types of penetrative sex with HIV risk. This issue
may be especially pronounced for trans men who may be at risk of
HIV from receptive genital sex [35,36]. Future efforts must ensure
that eligibility questions are trans inclusive and reflect the diversity
of sexual practice (and associated HIV risks) in these groups.
The landscape of sexual health provision has changed in England
and Wales since RCT recruitment. Firstly, austerity and health service
rationalisation has led to the closure of many sexual health clinics.
Secondly, the COVID-19 crisis has led to increased difficulties in ser-
vice access, some potentially enduring. It is therefore likely that moti-
vations to access HIVST for all groups, trans people included, will now
be increasingly driven by lack of choice.
Engaging a peer researcher in the qualitative study design, data
collection and analysis is a key strength of this work, leading to rich,
nuanced data elaborating on RCT findings.
In this modest sized RCT, HIVST increased uptake testing and fre-
quency among trans men and trans people overall, without leading to
adverse events. We did not identify any HIV infections in this group,
potentially because of small numbers participating. Trans people face
significant barriers to HIV testing services, which HIVST substantially
ameliorates. The SELPHI intervention was highly acceptable and val-
ued for providing a simple kit and good overall experience. Recruit-
ment was challenging; future research and implementation activities
should be attentive to developing innovative ways to engage trans
people with HIVST interventions that are specifically tailored to their
needs. Peer led approaches are critical to achieving this.Declaration of Competing Interest
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